• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

洛普雷斯干预试验:急性心肌梗死幸存者美托洛尔多中心研究。洛普雷斯干预试验研究组。

The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. Lopressor Intervention Trial Research Group.

出版信息

Eur Heart J. 1987 Oct;8(10):1056-64.

PMID:2890522
Abstract

The Lopressor Intervention Trial (LIT) was a double-blind, randomized, placebo-controlled, multicentre study designed to evaluate the effect of oral metoprolol on overall mortality in patients surviving a recent acute myocardial infarction. Patient enrollment began in August 1979 and ended on 15 April 1982, with 2395 patients (1200 on placebo and 1195 on metoprolol). Hospitalized patients, 45 to 74 years of age, began therapy from 6 to 16 days after their myocardial infarction. Following a short titration period, maintenance therapy with metoprolol 100 mg b.i.d. or placebo was continued for up to 1 year. Enrollment was prematurely terminated because of a progressive and marked decline in patient accession; it was not feasible to reach the original goal of 3200 patients in a practical period of time. This target sample size was based on an anticipated 1 year placebo mortality rate of 10%, a 50% reduction in total mortality with metoprolol and premature discontinuation of study medication in no more than 15% of patients in the metoprolol group. Two primary analyses were planned: total mortality among all randomized patients at 7 and at 12 months of trial entry. After 7 months of treatment there were 54 deaths in the placebo group and 42 deaths in the metoprolol group. After 1 year there were 62 deaths in the placebo group and 65 in the metoprolol group. Thus, the 1 year placebo mortality rate of 5.2% was half that predicted at the outset. In addition, study medication was prematurely discontinued in over 30% of patients in the metoprolol group.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

洛普雷斯干预试验(LIT)是一项双盲、随机、安慰剂对照的多中心研究,旨在评估口服美托洛尔对近期急性心肌梗死存活患者总体死亡率的影响。患者招募于1979年8月开始,1982年4月15日结束,共有2395名患者(1200名服用安慰剂,1195名服用美托洛尔)。45至74岁的住院患者在心肌梗死后6至16天开始治疗。经过短暂的滴定期后,继续使用美托洛尔100 mg每日两次或安慰剂进行维持治疗,最长持续1年。由于患者入组人数逐渐显著下降,招募提前终止;在实际时间段内达到3200名患者的原始目标是不可行的。这个目标样本量是基于预期的1年安慰剂死亡率10%、美托洛尔使总死亡率降低50%以及美托洛尔组不超过15%的患者提前停用研究药物。计划进行两项主要分析:所有随机分组患者在试验入组7个月和12个月时的总死亡率。治疗7个月后,安慰剂组有54例死亡,美托洛尔组有42例死亡。1年后,安慰剂组有62例死亡,美托洛尔组有65例死亡。因此,1年安慰剂死亡率5.2%仅为最初预测值的一半。此外,美托洛尔组超过30%的患者提前停用了研究药物。(摘要截短至250字)

相似文献

1
The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. Lopressor Intervention Trial Research Group.洛普雷斯干预试验:急性心肌梗死幸存者美托洛尔多中心研究。洛普雷斯干预试验研究组。
Eur Heart J. 1987 Oct;8(10):1056-64.
2
Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group.美托洛尔治疗急性心肌梗死(MIAMI)。一项随机安慰剂对照国际试验。MIAMI试验研究组
Eur Heart J. 1985 Mar;6(3):199-226.
3
The Göteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction.哥德堡美托洛尔试验。对急性心肌梗死死亡率和发病率的影响。
Circulation. 1983 Jun;67(6 Pt 2):I26-32.
4
Göteborg Metoprolol Trial: mortality and causes of death.哥德堡美托洛尔试验:死亡率及死因
Am J Cardiol. 1984 Jun 25;53(13):9D-14D.
5
European Infarction Study (E.I.S.). A secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality.欧洲心肌梗死研究(E.I.S.)。一项关于心肌梗死后使用氧烯洛尔缓释剂的二级预防研究:发病率和死亡率。
Eur Heart J. 1984 Mar;5(3):189-202.
6
Central haemodynamics in acute myocardial infarction. Natural history, relation to enzyme release and effects of metoprolol.急性心肌梗死的中心血流动力学。自然病史、与酶释放的关系及美托洛尔的作用。
Acta Med Scand Suppl. 1986;709:1-47.
7
Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Second Chinese Cardiac Study (CCS-2) Collaborative Group.第二项中国心脏研究(CCS-2)的原理、设计与组织:一项针对疑似急性心肌梗死患者的氯吡格雷联合阿司匹林以及美托洛尔的随机试验。第二项中国心脏研究(CCS-2)协作组
J Cardiovasc Risk. 2000 Dec;7(6):435-41.
8
The Diabetic Postoperative Mortality and Morbidity (DIPOM) trial: rationale and design of a multicenter, randomized, placebo-controlled, clinical trial of metoprolol for patients with diabetes mellitus who are undergoing major noncardiac surgery.糖尿病患者术后死亡率和发病率(DIPOM)试验:一项针对接受非心脏大手术的糖尿病患者进行的美托洛尔多中心、随机、安慰剂对照临床试验的原理与设计。
Am Heart J. 2004 Apr;147(4):677-83. doi: 10.1016/j.ahj.2003.10.030.
9
Effect of metoprolol on death and cardiac events during a 2-year period after coronary artery bypass grafting. The MACB Study Group.美托洛尔对冠状动脉旁路移植术后2年内心脏死亡及心脏事件的影响。MACB研究组。
Eur Heart J. 1995 Dec;16(12):1825-32.
10
Göteborg Metoprolol Trial: design, patient characteristics and conduct.哥德堡美托洛尔试验:设计、患者特征与实施情况
Am J Cardiol. 1984 Jun 25;53(13):3D-8D.

引用本文的文献

1
Beta-blockers in patients without heart failure after myocardial infarction.心肌梗死后无心力衰竭的患者使用β受体阻滞剂。
Cochrane Database Syst Rev. 2021 Nov 5;11(11):CD012565. doi: 10.1002/14651858.CD012565.pub2.
2
Comparison of Metoprolol Versus Carvedilol After Acute Myocardial Infarction.比较美托洛尔与卡维地洛在急性心肌梗死后的应用。
Am J Cardiol. 2021 May 15;147:1-7. doi: 10.1016/j.amjcard.2021.02.010. Epub 2021 Feb 20.
3
From Clinical Trial Efficacy to Real-Life Effectiveness: Why Conventional Metrics do not Work.从临床试验疗效到实际生活有效性:为何传统指标行不通。
Drugs Real World Outcomes. 2019 Sep;6(3):125-132. doi: 10.1007/s40801-019-0159-z.
4
β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature.β受体阻滞剂在高血压、糖尿病、心力衰竭及急性心肌梗死中的应用:文献综述
Open Heart. 2015 Mar 21;2(1):e000230. doi: 10.1136/openhrt-2014-000230. eCollection 2015.
5
Type of β-blocker use among patients with versus without diabetes after myocardial infarction.心梗后伴或不伴糖尿病患者β受体阻滞剂的使用类型。
Am Heart J. 2014 Sep;168(3):273-279.e1. doi: 10.1016/j.ahj.2014.04.018. Epub 2014 Jun 9.
6
Beta blocker use after acute myocardial infarction in the patient with normal systolic function: when is it "ok" to discontinue?收缩功能正常的患者急性心肌梗死后使用β受体阻滞剂:何时停药“合适”?
Curr Cardiol Rev. 2012 Feb;8(1):77-84. doi: 10.2174/157340312801215764.
7
Real-world algorithms for the optimal use of drugs and devices in the patient post myocardial infarction and the future of post myocardial infarction management.心肌梗死后患者药物和器械最佳使用的真实世界算法及心肌梗死后管理的未来。
Clin Cardiol. 2005 Nov;28(11 Suppl 1):I58-63. doi: 10.1002/clc.4960281310.
8
Reducing the risks of sudden death and heart failure post myocardial infarction: utility of optimized pharmacotherapy.降低心肌梗死后猝死和心力衰竭的风险:优化药物治疗的效用
Clin Cardiol. 2005 Nov;28(11 Suppl 1):I19-27. doi: 10.1002/clc.4960281305.
9
Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 2: Beta-blockers.选择高血压管理中的一线药物:证据有哪些?2:β受体阻滞剂。
CMAJ. 2000 Jul 25;163(2):188-92.
10
Calcium antagonists during and after myocardial infarction.心肌梗死期间及之后使用的钙拮抗剂。
Drugs. 1996 Feb;51(2):216-25. doi: 10.2165/00003495-199651020-00003.